Faeth Therapeutics FTH
NASDAQ FTH
$17.08 -3.02 (-15.02%)
At close: Oct 23, 2026 · 4:00 PM EDT

Faeth Therapeutics (FTH) Gains from Sales and Divestitures (2021 - 2025)

Updated

Faeth Therapeutics' Gains from Sales and Divestitures came in at -$1,000 for Q3 2025.

Analysis

Faeth Therapeutics (FTH) Gains from Sales and Divestitures (2021 - 2025) Analysis & Trends

Going back to Q2 2021, Faeth Therapeutics' Gains from Sales and Divestitures data covers 4 quarters.

  • The five-year range for quarterly Gains from Sales and Divestitures is -$40,000 (Q2 2025) to $20,000 (Q1 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 Faeth Therapeutics 98.59 Mn -336.87 Mn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 -1,000.00
Jun 30, 2025 -40,000.00
Mar 31, 2025 20,000.00
Jun 30, 2021 -28,000.00
API Access

Faeth Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=FTH&period=max&api_key=YOUR_API_KEY